Clinical considerations in Parkinson's disease cell therapy

被引：6

作者：

Xue, Jun ^{[1
,2
]}

Wu, Yifan ^{[1
,2
]}

Bao, Yuting ^{[1
,2
]}

Zhao, Minglai ^{[1
,2
]}

Li, Fangzhou ^{[1
,2
]}

Sun, Jing ^{[3
]}

Sun, Yimin ^{[4
]}

Wang, Jian ^{[4
]}

Chen, Liang ^{[1
,2
]}

Mao, Ying ^{[1
,2
]}

Schweitzer, Jeffrey S. ^{[5
]}

Song, Bin ^{[1
,2
]}

机构：

[1] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200040, Peoples R China

[2] Fudan Univ, Shanghai Clin Med Ctr Neurosurg, Neurosurg Inst,Shanghai Key Lab Brain Funct & Res, Natl Ctr Neurol Disorders, Shanghai 200040, Peoples R China

[3] Fudan Univ, MOE Frontiers Ctr Brain Sci, Inst Translat Brain Res, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China

[4] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Inst Neurol,Natl Clin Res Ctr Aging & Med, Shanghai 200032, Peoples R China

[5] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA

来源：

AGEING RESEARCH REVIEWS | 2023年 / 83卷

基金：

上海市自然科学基金; 中国国家自然科学基金;

关键词：

Parkinson?s disease; Cell therapy; Dopamine cells; Transplantation; Clinical trial; FETAL DOPAMINE NEURONS; IMPROVES XENOGRAFT SURVIVAL; GRAFT-INDUCED DYSKINESIAS; RIGHT CAUDATE-NUCLEUS; LONG-TERM SURVIVAL; MESENCEPHALIC TISSUE; PRIMATE MODEL; NIGRAL TRANSPLANTATION; GENE-THERAPY; NEURAL PROGENITORS;

D O I：

10.1016/j.arr.2022.101792

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Cell replacement therapy is an area of increasing interest for treating Parkinson's disease (PD). However, to become a clinically practical option for PD patients, it must first overcome significant barriers, including establishment of safe and standardized surgical procedures, determination of appropriate perioperative medication regimens, demonstration of long-term graft survival and incorporation, and standardized, clinically meaningful follow-up measures. In this review, we will describe the current status of cell therapy for PD with special attention to these critical requirements, to define guideposts on the road to bring the benefit of this therapy to the Parkinson's clinic.

引用

页数：20

共 50 条

[31] STEM CELL THERAPY IN PARKINSON'S DISEASE
Offen, Daniel
NEUROPEPTIDES, 2009, 43 (02) : 167 - 168
[32] Cell reprogramming therapy for Parkinson's disease
Wenjing Dong
Shuyi Liu
Shangang Li
Zhengbo Wang
Neural Regeneration Research, 2024, (11) : 2444 - 2455
[33] Stem cell therapy for Parkinson's disease
不详
FUTURE NEUROLOGY, 2006, 1 (02) : 125 - 125
[34] Stem cell therapy for Parkinson's disease
Björklund, A
JOURNAL OF BIOTECHNOLOGY, 2005, 118 : S66 - S66
[35] Cell therapy and transplantation in Parkinson's disease
Lindvall, O
Hagell, P
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (04) : 356 - 361
[36] Cell therapy for Parkinson's disease: Only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease
Linazasoro, Gurutz
CELL TRANSPLANTATION, 2006, 15 (06) : 463 - 473
[37] Diagnosis and clinical therapy for Parkinson's disease dementia
Wenzel, S.
Mollenhauer, B.
Trenkwalder, C.
NERVENARZT, 2006, 77 (12): : 1439 - +
[38] Interim Clinical Assessment of a Neural Stem Cell Based Therapy for Parkinson's Disease
Kern, Russell
Garitaonandia, Ibon
Gonzalez, Rodolfo
Sherman, Glenn
Noskov, Alexander
Cardiff, Dylan
Christiansen-Weber, Trudy
Semechkin, Andrey
Braine, Emma
Shahrul, Azmin
Nair, Girish
Evans, Andrew
NEUROLOGY, 2018, 90
[39] Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease
Master, Zubin
McLeod, Marcus
Mendez, Ivar
JOURNAL OF MEDICAL ETHICS, 2007, 33 (03) : 169 - 173
[40] Cell Transplantation and Gene Therapy in Parkinson's Disease
Wakeman, Dustin R.
Dodiya, Hemraj B.
Kordower, Jeffrey H.
MOUNT SINAI JOURNAL OF MEDICINE, 2011, 78 (01): : 126 - 158

← 1 2 3 4 5 →